P/OSPeptideOS evidence & status map
OPEN SOURCE MEDICINE FOUNDATIONLast reviewed 2026-10-14No dosing · no vendors · no advicesource
PeptideOS · therapeutic peptides, approved to gray market

What is the evidence that it works in people? Is it legal where you are?

An evidence and regulatory map with no dosing, no vendors and no advice. Every compound gets the same treatment: evidence tier first, regulatory status from primary sources, then what nobody knows. Mechanism comes last.

8 of 37compounds here have no published randomised human trial for any use. 22 have at least one claimed use with none.
37 compounds

Sorted by the best-supported use, strongest first. Tiers run from E1 multiple adequate RCTs to E8 no published efficacy evidence in any model; colour encodes knowledge, not danger (rubric). Each small bar marks one claimed use.

E1Multiple adequately powered RCTs, consistent

Afamelanotide

A · Approved
Melanotan-1, MT-1, [Nle4, D-Phe7]-alpha-MSH
Phototoxicity in erythropoietic protoporphyria (adults) (E1); Nonsegmental vitiligo (with narrowband UV-B phototherapy) (E3); Cosmetic tanning in healthy people (gray-market 'Melanotan-1' claim) (E3)
safety S2reviewed 2026-10-10

Bremelanotide

A · Approved
PT-141, Vyleesi
Hypoactive sexual desire disorder (HSDD) in premenopausal women (E1); Erectile dysfunction in men (gray-market claim; not an approved use) (E3)
safety S2reviewed 2026-10-10

Cagrilintide

B · Investig.
CagriSema (fixed co-formulation with semaglutide)
Weight management in adults with overweight or obesity, with or without type 2 diabetes (cagrilintide plus semaglutide, CagriSema) (E1); Weight management in adults with overweight or obesity (cagrilintide alone) (E2)
safety S2reviewed 2026-10-10

Desmopressin

A · Approved
Desmopressin acetate, DDAVP, 1-deamino-8-D-arginine vasopressin
Nocturia due to nocturnal polyuria in adults (E1); Primary nocturnal enuresis in children (E1); Central diabetes insipidus (E4); Haemophilia A and von Willebrand disease (bleeding prevention) (E4)
safety S1reviewed 2026-10-10

Icatibant

A · Approved
Icatibant acetate, HOE 140, Firazyr
Acute attacks of hereditary angioedema (C1-inhibitor deficiency) (E1); ACE-inhibitor-induced angioedema (off-label) (E3)
safety S1reviewed 2026-10-10

Mazdutide

A · Approved
Xinermei
Weight reduction in obesity or overweight (E1); Type 2 diabetes: glycaemic control (E1)
safety S2reviewed 2026-10-10

Retatrutide

B · Investig.
Weight reduction in obesity or overweight (the main use it is sold for) (E1); Type 2 diabetes: glycaemic control (E2); Knee osteoarthritis pain with obesity (E2); Obstructive sleep apnoea with obesity (E2); Liver fat (metabolic dysfunction-associated steatotic liver disease) (E3)
safety S2reviewed 2026-10-10

Semaglutide

A · Approved
Ozempic, Wegovy, Rybelsus
Type 2 diabetes: glycaemic control and cardiovascular outcomes (E1); Chronic weight management (obesity or overweight) (E1); Early Alzheimer's disease (oral semaglutide) (E1); Heart failure with preserved ejection fraction and obesity (E2); Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis (E2); Knee osteoarthritis pain with obesity (E2); Alcohol use disorder (off-label, claimed) (E3)
safety S1reviewed 2026-10-10

Survodutide

B · Investig.
Weight reduction in obesity or overweight (E1); Liver fat in obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) (E2); Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis (E3)
safety S2reviewed 2026-10-10

Teriparatide

A · Approved
PTH(1-34), rhPTH(1-34), Parathyroid hormone (1-34)
Postmenopausal osteoporosis (fracture prevention) (E1); Osteoporosis in men (E2); Glucocorticoid-induced osteoporosis (E2); Acceleration of fracture healing (off-label claim) (E3)
safety S1reviewed 2026-10-10

Tesamorelin

A · Approved
Tesamorelin acetate, TH9507, Egrifta
Excess abdominal (visceral) fat in adults with HIV-associated lipodystrophy (E1); Fatty liver (NAFLD) in people with HIV (E3); Visceral fat and cardiometabolic markers in people without HIV (abdominal obesity) (E3); Cognition in older adults and mild cognitive impairment (E3)
safety S2reviewed 2026-10-10

Tirzepatide

A · Approved
Mounjaro, Zepbound
Type 2 diabetes: glycaemic control and cardiovascular outcomes (E1); Chronic weight management (obesity or overweight) (E1); Obstructive sleep apnoea with obesity (E1); Heart failure with preserved ejection fraction and obesity (E2); Metabolic dysfunction-associated steatohepatitis (MASH) (E3)
safety S1reviewed 2026-10-10

E2At least one adequately powered RCT

E3Small, underpowered or conflicting RCTs

AOD-9604

C · Gray market
AOD9604, Tyr-hGH(177-191)
Weight loss and fat reduction in obesity (E3); Joint cartilage and osteoarthritis (E6)
safety S2reviewed 2026-10-10

BPC-157

C · Gray market
BPC 157, Body Protection Compound-157, Bepecin
Ulcerative colitis and inflammatory bowel disease (E3); Interstitial cystitis (bladder pain syndrome) (E4); Tendon, ligament, muscle and joint injury (E5); Stomach and gut lining injury (ulcers, NSAID damage, 'leaky gut') (E6)
safety S4reviewed 2026-10-10

CJC-1295

C · Gray market
CJC-1295 with DAC, CJC 1295
Raising GH and IGF-1 levels (pharmacodynamic marker, healthy adults) (E3); Growth in GHRH deficiency (E6); Muscle gain, fat loss, recovery, sleep and anti-ageing (gray-market claims) (E8); Visceral fat in people with HIV (E8)
safety S3reviewed 2026-10-10

Elamipretide

A · Approved
SS-31, MTP-131, Bendavia
Barth syndrome (muscle strength, exercise capacity, fatigue) (E3); Primary mitochondrial myopathy (E3); Dry age-related macular degeneration with geographic atrophy (E3); Age-related decline in muscle function and exercise capacity (anti-ageing claims) (E3)
safety S2reviewed 2026-10-10

GHK-Cu

C · Gray market
Copper peptide GHK-Cu, Copper tripeptide, Glycyl-L-histidyl-L-lysine copper(II)
Diabetic foot ulcers (topical gel) (E3); Skin ageing, wrinkles and post-procedure skin (topical cosmetic) (E3); Injected GHK-Cu for tissue healing, inflammation or anti-ageing (E6)
safety S3reviewed 2026-10-10

GHRP-6

C · Gray market
Growth hormone-releasing peptide-6, Growth hormone releasing hexapeptide
Growth hormone release (E3); Acute ischaemic stroke (with epidermal growth factor) (E3)
safety S3reviewed 2026-10-10

Hexarelin

C · Gray market
Examorelin
Growth hormone release (E3); Muscle mass and body composition (E4); Short stature in children (E4)
safety S3reviewed 2026-10-10

Ipamorelin

C · Gray market
Ipamorelin acetate
Postoperative ileus (E3); Bone growth and bone mineral content (E6); Muscle gain, fat loss, recovery, sleep and anti-ageing (gray-market claims) (E8)
safety S3reviewed 2026-10-10

LL-37

C · Gray market
Cathelicidin LL-37, Human cathelicidin antimicrobial peptide, Ropocamptide
Chronic venous leg ulcers unresponsive to standard care (topical synthetic LL-37) (E3); Diabetic foot ulcers (topical synthetic LL-37) (E3); Systemic or chronic infections and immune support (injected LL-37, gray-market claims) (E6)
safety S3reviewed 2026-10-10

Melanotan II

C · Gray market
Melanotan-II, MT-II, Melanotan 2
Erectile dysfunction and sexual desire in men (E3); Skin tanning (the main gray-market claim) (E4); Appetite suppression / weight loss (gray-market claim) (E6)
safety S4reviewed 2026-10-10

Selank

C · Gray market
Selank acetate, TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro
Anxiety disorders (E3); Cognitive enhancement (memory, attention) (E6); Stroke (E6)
safety S4reviewed 2026-10-10

TB-500

C · Gray market
TB500, Thymosin beta-4 fragment (LKKTETQ), Ac-LKKTETQ
Chronic skin wounds and ulcers (full-length thymosin beta-4, not TB-500) (E3); Injury recovery: tendon, ligament, muscle and skin wounds (TB-500 fragment itself) (E6)
safety S5reviewed 2026-10-10

Thymalfasin

C · Gray market
Thymosin alpha-1, Thymosin α1, Ta1
Chronic hepatitis B (E3); Chronic hepatitis C (E3); Sepsis (E3); Cancer (adjunct to chemotherapy; metastatic melanoma as the main tested setting) (E3); COVID-19 (E4); Chronic fatigue syndrome (ME/CFS) (E8)
safety S2reviewed 2026-10-10

E4Uncontrolled or non-randomised human trials

E6Animal models only